These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 38662701

  • 1. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
    Kura K, Stolk WA, Basáñez MG, Collyer BS, de Vlas SJ, Diggle PJ, Gass K, Graham M, Hollingsworth TD, King JD, Krentel A, Anderson RM, Coffeng LE.
    Clin Infect Dis; 2024 Apr 25; 78(Supplement_2):S93-S100. PubMed ID: 38662701
    [Abstract] [Full Text] [Related]

  • 2. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment.
    Njenga SM, Kanyi H, Okoyo C, Githinji E, Mwatele C, Matendechero SH, Omondi WP, Gitahi PN, Owaga C, Onsongo JK, Gass K.
    PLoS Negl Trop Dis; 2024 Jul 25; 18(7):e0011942. PubMed ID: 38976718
    [Abstract] [Full Text] [Related]

  • 3. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S, Toothong T, Boondej P, Thammapalo S, Khuanyoung N, Santabutr W, Prempree P, Gopinath D, Ramaiah KD.
    Infect Dis Poverty; 2019 May 27; 8(1):38. PubMed ID: 31130143
    [Abstract] [Full Text] [Related]

  • 4. Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
    Stolk WA, Prada JM, Smith ME, Kontoroupis P, de Vos AS, Touloupou P, Irvine MA, Brown P, Subramanian S, Kloek M, Michael E, Hollingsworth TD, de Vlas SJ.
    Clin Infect Dis; 2018 Jun 01; 66(suppl_4):S260-S266. PubMed ID: 29860286
    [Abstract] [Full Text] [Related]

  • 5. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
    Jambulingam P, Subramanian S, de Vlas SJ, Vinubala C, Stolk WA.
    Parasit Vectors; 2016 Sep 13; 9(1):501. PubMed ID: 27624157
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L, Laman M, Howard C, Kotty B, Samuel A, Bjerum C, O'Brian K, Kumai S, Amuga M, Lorry L, Kerry Z, Kualawi M, Karl S, Makita L, John LN, Bieb S, Wangi J, Weil GJ, Goss CW, Tisch DJ, Pomat W, King CL, Robinson LJ.
    PLoS Negl Trop Dis; 2022 Feb 13; 16(2):e0010096. PubMed ID: 35139070
    [Abstract] [Full Text] [Related]

  • 7. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, Rahi M, Somani RK, Suryaprakash MK, Dwivedi GP, Weil GJ.
    PLoS Negl Trop Dis; 2021 Feb 13; 15(2):e0009069. PubMed ID: 33591979
    [Abstract] [Full Text] [Related]

  • 8. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD, Das PK, Vanamail P, Pani SP.
    Trop Med Int Health; 2003 Dec 13; 8(12):1082-92. PubMed ID: 14641843
    [Abstract] [Full Text] [Related]

  • 9. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
    de Souza DK, Ahorlu CS, Adu-Amankwah S, Otchere J, Mensah SK, Larbi IA, Mensah GE, Biritwum NK, Boakye DA.
    Trials; 2017 Oct 02; 18(1):448. PubMed ID: 28969715
    [Abstract] [Full Text] [Related]

  • 10. Endpoints for lymphatic filariasis programs.
    Grady CA, de Rochars MB, Direny AN, Orelus JN, Wendt J, Radday J, Mathieu E, Roberts JM, Streit TG, Addiss DG, Lammie PJ.
    Emerg Infect Dis; 2007 Apr 02; 13(4):608-10. PubMed ID: 17553278
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings.
    James A, Coffeng LE, Blok DJ, King JD, de Vlas SJ, Stolk WA.
    Clin Infect Dis; 2024 Apr 25; 78(Supplement_2):S131-S137. PubMed ID: 38662696
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T, Djuardi Y, Christian M, Iskandar E, Alfian R, Maylasari R, Destani Y, Lomiga A, Minggu D, Lew D, Bogus J, Weil GJ, Fischer PU.
    PLoS Negl Trop Dis; 2021 Mar 25; 15(3):e0009294. PubMed ID: 33780481
    [Abstract] [Full Text] [Related]

  • 15. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
    Bockarie MJ, Alexander ND, Hyun P, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW.
    Lancet; 1998 Jan 17; 351(9097):162-8. PubMed ID: 9449870
    [Abstract] [Full Text] [Related]

  • 16. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
    Ramaiah KD, Vanamail P, Pani SP, Yuvaraj J, Das PK.
    Trop Med Int Health; 2002 Sep 17; 7(9):767-74. PubMed ID: 12225508
    [Abstract] [Full Text] [Related]

  • 17. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
    Minetti C, Tettevi EJ, Mechan F, Prada JM, Idun B, Biritwum NK, Osei-Atweneboana MY, Reimer LJ.
    PLoS Negl Trop Dis; 2019 Jan 17; 13(1):e0006994. PubMed ID: 30608931
    [Abstract] [Full Text] [Related]

  • 18. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
    Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Grobler AC, Robinson LJ, Kaldor JM, Steer AC.
    Clin Infect Dis; 2021 Sep 15; 73(6):994-1002. PubMed ID: 33728462
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J, Basáñez MG, O'Hanlon SJ, Tekle AH, Wanji S, Zouré HG, Rebollo MP, Pullan RL.
    Parasit Vectors; 2018 Jan 31; 11(1):70. PubMed ID: 29382363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.